NovaBridge Biosciences H1FY26 Update: $216m cash, Phase 3 plans
- NovaBridge holds $216 million in cash and investments, maintaining a debt-free balance sheet
- Gvostomig received FDA Fast Track designation; Phase 3 study targeted for Q4 2026 initiation
- VIS101 advances to Phase 2b study in H2 2026 following positive Phase 2a results
- Financial runway extends through 2028, covering key oncology and ophthalmology milestones
- Company explores European partnerships and women's health opportunities via business development
*this image is generated using AI for illustrative purposes only.
NovaBridge Biosciences (NASDAQ: NBP) reported a debt-free balance sheet with $216 million in cash and investments as of June 30, 2026. The company stated this position supports clinical milestones for its lead oncology and ophthalmology programs through 2028.
The biotechnology firm advanced its lead oncology asset, Gvostomig, and ophthalmology asset, VIS101, during the first half of 2026. Management emphasized disciplined capital allocation and strategic partnerships to bridge the gap between early-stage science and patient impact.
Financial Position and Runway
Kyler Lei, Chief Financial Officer, detailed the company's liquidity position. NovaBridge held approximately $191 million in cash and cash equivalents and $25 million in equity investments at fair value. The balance sheet remains debt-free.
| Metric | Value (as of June 30, 2026) |
|---|---|
| Total Cash and Investments | $216 million |
| Cash and Cash Equivalents | $191 million |
| Equity Investments | $25 million |
| Debt Status | Debt-free |
Management indicated the current financial resources support key inflection points, including Phase 2 enrollment completion for Gvostomig and potential Phase 3 initiation by year-end 2026. The runway extends through the anticipated Phase 3 interim data readout for Gvostomig in 2028.
Pipeline Progress: Oncology and Ophthalmology
Srishti Gupta, Chief Executive Officer, outlined progress across two lead programs. Gvostomig, an oncology therapy, received Fast Track designation from the FDA in June for use in combination with nivolumab and chemotherapy. The company anticipates presenting updated Phase 1b dose expansion data at ESMO in October. A Phase 3 study is targeted for initiation as early as the fourth quarter of 2026, subject to planning and financing.
VIS101, developed through majority-owned subsidiary VSARA, showed positive Phase 2a results in retinal vascular disease. The company is preparing to initiate a Phase 2b study in the second half of 2026 to define optimal dosing before advancing toward global Phase 3 development.
Strategic Expansion and Business Development
NovaBridge is exploring opportunities in the European market and women's health. Gupta noted conversations with European commercial organizations to combine NovaBridge's business development and clinical capabilities with local market access expertise. The strategy focuses on assets that offer differentiation compared to reimbursed standards of care.
In women's health, the company is evaluating mechanisms of action for conditions such as endometriosis, menopause, and polycystic ovarian syndrome. Management highlighted unmet needs in areas disproportionately affecting women, including osteoporosis and sarcopenia.
Asset Screening Evolution
Gupta described a shift in asset screening criteria since joining the company. The focus has moved from purely financial underwriting to assessing clinical development pathways and commercial practicality. The team now evaluates whether a clear path exists for payer adoption and physician differentiation before advancing assets.
What the Numbers Show
The composition of NovaBridge's liquidity reveals a conservative approach to capital preservation. With $191 million in cash equivalents representing approximately 88% of total liquid assets, the company prioritizes immediate operational flexibility over higher-yield but less liquid investments. This structure aligns with the stated strategy of funding specific clinical milestones without external dilution until Phase 3 data emerges in 2028.
How might the initiation of Gvostomig's Phase 3 trial in late 2026 impact NovaBridge's cash burn rate and potential need for external financing before the 2028 data readout?
What specific criteria will NovaBridge use to prioritize its pipeline expansion into women's health conditions like endometriosis versus continuing to focus resources on oncology and ophthalmology?
Could the company's strategy of seeking European commercial partnerships for local market access lead to equity dilution or licensing fees that affect its current debt-free balance sheet?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
